NASDAQ : BIOA
BioAge Labs, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 5.94 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 272.63M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 269.41M |
| Enterprise Value | -109.01M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 45.90M |
| Shares Outstanding | 45.90M |
| Shares Change (YoY) | +43.29% |
| Shares Change (QoQ) | +5.55% |
| Owned by Insiders (%) | 2.36% |
| Owned by Institutions (%) | 76.96% |
| Float | 39.19M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.02 |
| Forward PS | 88.45 |
| PB Ratio | 0.72 |
| P/TBV Ratio | 0.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 17.19 |
| Quick Ratio | 16.75 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -378.19 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -28.21% |
| Return on Assets (ROA) | -18.47% |
| Return on Invested Capital (ROIC) | -19.50% |
| Return on Capital Employed (ROCE) | -28.14% |
| Weighted Average Cost of Capital (WACC) | 10.17% |
| Revenue Per Employee | $167,016 |
| Profits Per Employee | -$1.52M |
| Employee Count | 62 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.08 |
| 52-Week Price Change | -23.57% |
| 50-Day Moving Average | 7.39 |
| 200-Day Moving Average | 15.82 |
| Relative Strength Index (RSI) | 43.37 |
| Average Volume (20 Days) | 926,159 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.43M |
| Short Previous Month | 3.27M |
| Short % of Shares Out | 7.48% |
| Short % of Float | 8.76% |
| Short Ratio (days to cover) | 3.88 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 10.36M |
| Gross Profit | -77.43M |
| Operating Income | -106.27M |
| Pretax Income | -94.46M |
| Net Income | -94.46M |
| EBITDA | -106.02M |
| EBIT | -106.27M |
| Loss Per Share | -$2.37 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 318.75M |
| Total Debt | 2.84M |
| Net Cash | 378.43M |
| Net Cash Per Share | $8.25 |
| Equity (Book Value) | 374.91M |
| Book Value Per Share | 8.19 |
| Working Capital | 311.10M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -87.60M |
| Capital Expenditures | -488,000 |
| Depreciation & Amortization | 251,000 |
| Net Borrowing | -5.00M |
| Free Cash Flow | -88.09M |
| FCF Per Share | -$1.92 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -1,026.28% |
| Pretax Margin | -912.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -43.29% |
| Shareholder Yield | -43.29% |
| Earnings Yield | -40.39% |
| FCF Yield | -32.70% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $32.56 |
| Price Target Difference | 454.69% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | -32.14% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 12.72 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |